Breast Cancer Therapeutics in Major Developed Market Growth & Research Report 2021 Radiant Insights, Inc
Summary Breast cancer, a malignant neoplasm, is the second most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. The number of women diagnosed with breast cancer has increased over the past few decades, but the number of deaths has declined due to earlier diagnosis and better treatment options. Breast cancer treatment has been revolutionized in the past four decades, especially with increasing usage of targeted therapies. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies, and targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response. Read Complete Report With TOC @ http://www.radiantinsights.com/research/breast-cancer-therapeutics-in-major-developed-markets Scope The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent. - What are the competitive advantages of the existing novel drugs? With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates. - Which classes of novel drugs are most prominent within the pipeline? - Is there strong potential for the pipeline to address unmet needs within the breast cancer market? Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%. - How do failure rates vary by product stage of development, molecule type, and mechanism of action? - How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development? Over the 2014–2021 forecast period, the breast cancer therapeutics market in the eight major markets is expected to increase in value at a CAGR of 7.3%, from $10.4 billion to over $17.2 billion.
Summary
Breast cancer, a malignant neoplasm, is the second most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. The number of women diagnosed with breast cancer has increased over the past few decades, but the number of deaths has declined due to earlier diagnosis and better treatment options.
Breast cancer treatment has been revolutionized in the past four decades, especially with increasing usage of targeted therapies. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies, and targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response.
Read Complete Report With TOC @ http://www.radiantinsights.com/research/breast-cancer-therapeutics-in-major-developed-markets
Scope
The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent.
- What are the competitive advantages of the existing novel drugs?
With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates.
- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the breast cancer market?
Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?
Over the 2014–2021 forecast period, the breast cancer therapeutics market in the eight major markets is expected to increase in value at a CAGR of 7.3%, from $10.4 billion to over $17.2 billion.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Figure 34: <strong>Breast</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Five Lead<strong>in</strong>g European <strong>Market</strong>s, <strong>Market</strong> Size ($m), 2014–<br />
<strong>2021</strong> 78<br />
Figure 35: <strong>Breast</strong> <strong>Cancer</strong> <strong>Market</strong>, Japan, Treatment Usage Patterns (‘000), 2014–<strong>2021</strong> 79<br />
Figure 36: <strong>Breast</strong> <strong>Cancer</strong> <strong>Market</strong>, Japan, Annual Cost of Therapy ($), 2014–<strong>2021</strong> 80<br />
Figure 37: <strong>Breast</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Japan, <strong>Market</strong> Size ($m), 2014–<strong>2021</strong> 81<br />
Figure 38: <strong>Breast</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Licens<strong>in</strong>g Deals by Region, 2006–2015 84<br />
Figure 39: <strong>Breast</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Licens<strong>in</strong>g Deals by Deal Value, 2006–2015 85<br />
Figure 40: <strong>Breast</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Number of Disclosed and Undisclosed Licens<strong>in</strong>g<br />
Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006–2015 86<br />
Figure 41: <strong>Breast</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Licens<strong>in</strong>g Deals by Stage of Development, Deal<br />
Value ($m) and Upfront Payment Value ($m), 2006–2015 87<br />
Figure 42: <strong>Breast</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Licens<strong>in</strong>g Deals by Molecule Type and Stage of<br />
Development, 2006–2015 88<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiant<strong>in</strong>sights.com/research/breast-cancertherapeutics-<strong>in</strong>-major-developed-markets<br />
Figure 43: <strong>Breast</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Co-development Deals by Region, 2006–2015 90<br />
Figure 44: <strong>Breast</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Number of Disclosed and Undisclosed Codevelopment<br />
Deals by Year and Value, 2006–2015 91<br />
Figure 45: <strong>Breast</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Co-development Deals by Stage of Development,<br />
2006–2015 92<br />
Figure 46: <strong>Breast</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Co-development Deals by Molecular Target,<br />
2006–2015 93<br />
About <strong>Radiant</strong> <strong>Insights</strong><br />
<strong>Radiant</strong> <strong>Insights</strong> is a platform for companies look<strong>in</strong>g to meet their market research and bus<strong>in</strong>ess<br />
<strong>in</strong>telligence requirements. We assist and facilitate organizations and <strong>in</strong>dividuals procure market research<br />
reports, help<strong>in</strong>g them <strong>in</strong> the decision mak<strong>in</strong>g process. We have a comprehensive collection of reports,<br />
cover<strong>in</strong>g over 40 key <strong>in</strong>dustries and a host of micro markets. In addition to over extensive database of<br />
reports, our experienced research coord<strong>in</strong>ators also offer a host of ancillary services such as, research<br />
partnerships/ tie-ups and customized research solutions.<br />
For More Information, Visit <strong>Radiant</strong> <strong>Insights</strong>
Change language